2017 - Distinguished Fellowship Award, American College of Cardiology (ACC)
2015 - Distinguished Scientist Award, American Heart Association
2013 - James B. Herrick Award for Outstanding Achievement in Clinical Cardiology, American Heart Association
Member of the Association of American Physicians
The scientist’s investigation covers issues in Internal medicine, Cardiology, Myocardial infarction, Heart failure and Surgery. His Internal medicine research is multidisciplinary, incorporating elements of Placebo and Endocrinology. His Cardiology research incorporates themes from ACE inhibitor and Blood pressure.
Marc A. Pfeffer combines subjects such as Captopril and Pravastatin with his study of Myocardial infarction. His Heart failure research is multidisciplinary, incorporating perspectives in Candesartan, Survival analysis, Proportional hazards model and Coronary artery disease. His Surgery study combines topics from a wide range of disciplines, such as Diabetes mellitus, Stroke, Clinical trial and Risk factor.
Internal medicine, Cardiology, Heart failure, Myocardial infarction and Ejection fraction are his primary areas of study. His Internal medicine study combines topics in areas such as Endocrinology and Surgery. His Cardiology study frequently draws parallels with other fields, such as Valsartan.
As a part of the same scientific family, Marc A. Pfeffer mostly works in the field of Heart failure, focusing on Placebo and, on occasion, Randomized controlled trial. His studies deal with areas such as Stroke, Captopril and Risk factor as well as Myocardial infarction. He interconnects Diastole and Atrial fibrillation in the investigation of issues within Ejection fraction.
His main research concerns Internal medicine, Cardiology, Heart failure, Ejection fraction and Heart failure with preserved ejection fraction. His work on Myocardial infarction, Hazard ratio and Spironolactone is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science. His Myocardial infarction research incorporates elements of Stroke, Framingham Risk Score and Sudden cardiac death.
His work carried out in the field of Cardiology brings together such families of science as Candesartan, Proportional hazards model and Renal function. His Heart failure study incorporates themes from Kidney disease, Valsartan and Atrial fibrillation. His research integrates issues of Interquartile range, Incidence, Cause of death, Clinical endpoint and Troponin T in his study of Ejection fraction.
Marc A. Pfeffer mainly investigates Internal medicine, Heart failure, Cardiology, Heart failure with preserved ejection fraction and Ejection fraction. Marc A. Pfeffer works mostly in the field of Internal medicine, limiting it down to topics relating to Diabetes mellitus and, in certain cases, Acute coronary syndrome. His research in Heart failure intersects with topics in Endocrinology and Baseline characteristics.
His studies in Cardiology integrate themes in fields like Candesartan, Aldosterone and Confidence interval. His Ejection fraction research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
F. M. Sacks;M. A. Pfeffer;L. A. Moye;J. L. Rouleau.
The New England Journal of Medicine (1996)
EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION. RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
Marc A. Pfeffer;Eugene Braunwald;Lemuel A. Moyé;Lofty Basta.
The New England Journal of Medicine (1992)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P. Cannon;Eugene Braunwald;Carolyn H. McCabe;Daniel J. Rader.
The New England Journal of Medicine (2004)
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
Mark J. Sarnak;Andrew S. Levey;Anton C. Schoolwerth;Josef Coresh.
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
M A Pfeffer;E Braunwald.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
John Jv McMurray;Jan Östergren;Karl Swedberg;Christopher B Granger.
The Lancet (2003)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Salim Yusuf;Marc A Pfeffer;Karl Swedberg;Christopher B Granger.
The Lancet (2003)
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Marc A. Pfeffer;John J.V. McMurray;Eric J. Velazquez;Jean-Lucien Rouleau.
The New England Journal of Medicine (2003)
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
Stuart J. Connolly;Janice Pogue;Robert G. Hart;Stefan H. Hohnloser.
The New England Journal of Medicine (2009)
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute
Sidney C. Smith;Jerilyn Allen;Steven N. Blair;Robert O. Bonow.
Journal of the American College of Cardiology (2006)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: